Abstract |
Human herpesviruses (HHV) 6 and 7 are ubiquitous infections that reactivate commonly in transplant recipients. However, clinical diseases due to these viruses are reported only in 1% of solid organ transplant recipients. Fever, rash and bone marrow suppression are the most common manifestations, but symptoms of tissue invasive disease may be observed. Treatment of HHV-6 and HHV-7 disease includes antiviral therapy and cautious reduction in immunosuppression. HHV-8 is an oncogenic gamma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients. Nonmalignant diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV-8. Reduction in immunosuppression is the first line treatment of HHV-8 infection. Other alternatives for treatment, especially for HHV-8 diseases not responsive to immuno-minimization strategies, are surgery and chemotherapy. Sirolimus has been shown to be a beneficial component for the treatment of Kaposi's sarcoma and the role of antivirals for HHV-8 infection is being investigated.
|
Authors | R R Razonable |
Journal | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
(Am J Transplant)
Vol. 13 Suppl 3
Pg. 67-77; quiz 77-8
(Feb 2013)
ISSN: 1600-6143 [Electronic] United States |
PMID | 23347215
(Publication Type: Journal Article)
|
Copyright | © Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons. |
Chemical References |
- Antiviral Agents
- Immunosuppressive Agents
- Sirolimus
|
Topics |
- Antiviral Agents
(therapeutic use)
- Herpesviridae Infections
(complications, etiology)
- Herpesvirus 6, Human
(metabolism)
- Herpesvirus 7, Human
(metabolism)
- Herpesvirus 8, Human
(metabolism)
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Organ Transplantation
(adverse effects)
- Sarcoma, Kaposi
(complications, drug therapy)
- Sirolimus
(therapeutic use)
|